Sarepta Therapeutics (Rare Pediatric Disease Priority Review Voucher)

Sarepta Therapeutics (Rare Pediatric Disease Priority Review Voucher) Overview

Founded 2007
Founded
Status Acquired/​Merged
Latest Deal Type Asset Purch.
Financing Rounds 1

Sarepta Therapeutics (Rare Pediatric Disease Priority Review Voucher) General Information

Description

A Priority Review Voucher for drugs. It helps to reduce the Food and Drug Administration's review period for a drug from ten months to six months, thereby potentially giving the company a crucial first-to-market advantage. The developer of a treatment for a neglected or rare pediatric disease can apply for a voucher from Food and Drug Administration (FDA).

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Primary Industry
Other Business Products and Services
Acquirer
Primary Office
  • 215 First Street
  • Cambridge, MA 02142
  • United States
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Sarepta Therapeutics (Rare Pediatric Disease Priority Review Voucher) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Sarepta Therapeutics (Rare Pediatric Disease Priority Review Voucher)‘s full profile, request access.

Request a free trial

Sarepta Therapeutics (Rare Pediatric Disease Priority Review Voucher) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Sarepta Therapeutics (Rare Pediatric Disease Priority Review Voucher)‘s full profile, request access.

Request a free trial